HepaCAM Inhibits Cell Proliferation and Invasion in Prostate Cancer by Suppressing Nuclear Translocation of the Androgen Receptor Via Its Cytoplasmic Domain

Overview

Journal Mol Med Rep

Specialty Molecular Biology

Date 2019 Jan 22

PMID 30664187

Citations 4

Authors

Qingfu Deng

Li Luo

Zhen Quan

Nanjing Liu

Zhongbo Du

Wei Sun

ChunLi Luo

Xiaohou Wu

Affiliations

Soon will be listed here.

Abstract

Hepatocyte cell adhesion molecule (HepaCAM) is a tumour suppressor. However, the mechanism of HepaCAM function in prostate cancer (PCa) remains unknown. In the present study, HepaCAM, androgen receptor (AR) and Ran were analysed in 46 PCa tissue samples using immunohistochemistry. Subsequently, the influence of HepaCAM and its cytoplasmic domain on cell proliferation, migration, and invasion, and associated proteins was examined using MTT, wound healing, Transwell and western blotting assays, respectively. Furthermore, nuclear translocation of AR and Ran was analysed using immunofluorescence and Western blot assays. The results demonstrated that HepaCAM expression was reduced in PCa, and there was an association between downregulation of HepaCAM and changes in the distribution of AR and Ran. Furthermore, HepaCAM, specifically the cytoplasmic domain, was involved in cell proliferation, migration and invasion. Nuclear translocation of AR was dependent on HepaCAM and its cytoplasmic domain. Additionally, HepaCAM suppression of the nuclear translocation of AR occurred via Ran. The results suggest that HepaCAM and its cytoplasmic domain suppress the nuclear translocation of AR via Ran in PCa. The cytoplasmic domain of HepaCAM may serve as a novel target for therapy in PCa.

Citing Articles

Identification of HEPACAM2 as a novel and specific marker of small cell carcinoma.

McColl K, Ajay A, Wang H, Wildey G, Yoon S, Grubb B Cancer. 2024; 131(1):e35557.

PMID: 39301750 PMC: 11694165. DOI: 10.1002/cncr.35557.

Identification of subclusters and prognostic genes based on GLS-associated molecular signature in ulcerative colitis.

Xie Y, Li J, Tao Q, Wu Y, Liu Z, Chen Y Sci Rep. 2024; 14(1):13102.

PMID: 38849409 PMC: 11161595. DOI: 10.1038/s41598-024-63891-2.

Glial Cell Adhesion Molecule (GlialCAM) Determines Proliferative versus Invasive Cell States in Glioblastoma.

De A, Lattier J, Morales J, Kelly J, Zheng X, Chen Z J Neurosci. 2023; 43(47):8043-8057.

PMID: 37722850 PMC: 10669794. DOI: 10.1523/JNEUROSCI.1401-23.2023.

HepaCAM‑PIK3CA axis regulates the reprogramming of glutamine metabolism to inhibit prostate cancer cell proliferation.

He Z, Gao Y, Li T, Yu C, Ou L, Luo C Int J Oncol. 2022; 60(4).

PMID: 35191516 PMC: 8878713. DOI: 10.3892/ijo.2022.5327.

References

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Taplin M, Balk S . Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem. 2004; 91(3):483-90. DOI: 10.1002/jcb.10653. View

Moh M, Lee L, Shen S . Cloning and characterization of hepaCAM, a novel Ig-like cell adhesion molecule suppressed in human hepatocellular carcinoma. J Hepatol. 2005; 42(6):833-41. DOI: 10.1016/j.jhep.2005.01.025. View

Moh M, Zhang C, Luo C, Lee L, Shen S . Structural and functional analyses of a novel ig-like cell adhesion molecule, hepaCAM, in the human breast carcinoma MCF7 cells. J Biol Chem. 2005; 280(29):27366-74. DOI: 10.1074/jbc.M500852200. View

Scher H, Sawyers C . Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005; 23(32):8253-61. DOI: 10.1200/JCO.2005.03.4777. View

Adam S, Gerace L . Cytosolic proteins that specifically bind nuclear location signals are receptors for nuclear import. Cell. 1991; 66(5):837-47. DOI: 10.1016/0092-8674(91)90431-w. View

Becker K, Rosivatz E, Blechschmidt K, Kremmer E, Sarbia M, Hofler H . Analysis of the E-cadherin repressor Snail in primary human cancers. Cells Tissues Organs. 2007; 185(1-3):204-12. DOI: 10.1159/000101321. View

Dehm S, Tindall D . Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol Endocrinol. 2007; 21(12):2855-63. DOI: 10.1210/me.2007-0223. View

Shank L, Kelley J, Gioeli D, Yang C, Spencer A, Allison L . Activation of the DNA-dependent protein kinase stimulates nuclear export of the androgen receptor in vitro. J Biol Chem. 2008; 283(16):10568-80. PMC: 7486792. DOI: 10.1074/jbc.M800810200. View

10.

Moh M, Zhang T, Lee L, Shen S . Expression of hepaCAM is downregulated in cancers and induces senescence-like growth arrest via a p53/p21-dependent pathway in human breast cancer cells. Carcinogenesis. 2008; 29(12):2298-305. DOI: 10.1093/carcin/bgn226. View

11.

Knudsen K, Scher H . Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res. 2009; 15(15):4792-8. PMC: 2842118. DOI: 10.1158/1078-0432.CCR-08-2660. View

12.

Chen Y, Clegg N, Scher H . Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol. 2009; 10(10):981-91. PMC: 2935850. DOI: 10.1016/S1470-2045(09)70229-3. View

13.

Bennett N, Gardiner R, Hooper J, Johnson D, Gobe G . Molecular cell biology of androgen receptor signalling. Int J Biochem Cell Biol. 2009; 42(6):813-27. DOI: 10.1016/j.biocel.2009.11.013. View

14.

Attard G, Cooper C, de Bono J . Steroid hormone receptors in prostate cancer: a hard habit to break?. Cancer Cell. 2009; 16(6):458-62. DOI: 10.1016/j.ccr.2009.11.006. View

15.

Xun C, Luo C, Wu X, Zhang Q, Yan L, Shen S . Expression of hepaCAM and its effect on proliferation of tumor cells in renal cell carcinoma. Urology. 2010; 75(4):828-34. DOI: 10.1016/j.urology.2009.11.024. View

16.

Zhang Q, Luo C, Wu X, Wang C, Xu X, Zhang Y . HepaCAM induces G1 phase arrest and promotes c-Myc degradation in human renal cell carcinoma. J Cell Biochem. 2011; 112(10):2910-9. DOI: 10.1002/jcb.23207. View

17.

Bluemn E, Nelson P . The androgen/androgen receptor axis in prostate cancer. Curr Opin Oncol. 2012; 24(3):251-7. PMC: 4161359. DOI: 10.1097/CCO.0b013e32835105b3. View

18.

Xu B, He Y, Wu X, Luo C, Liu A, Zhang J . Exploration of the correlations between interferon-γ in patient serum and HEPACAM in bladder transitional cell carcinoma, and the interferon-γ mechanism inhibiting BIU-87 proliferation. J Urol. 2012; 188(4):1346-53. DOI: 10.1016/j.juro.2012.06.005. View

19.

Wang Q, Luo C, Wu X, Du H, Song X, Fan Y . hepaCAM and p-mTOR closely correlate in bladder transitional cell carcinoma and hepaCAM expression inhibits proliferation via an AMPK/mTOR dependent pathway in human bladder cancer cells. J Urol. 2013; 190(5):1912-8. DOI: 10.1016/j.juro.2013.05.013. View

20.

Wang L, Hou Y, Sun Y, Zhao L, Tang X, Hu P . c-Ski activates cancer-associated fibroblasts to regulate breast cancer cell invasion. Mol Oncol. 2013; 7(6):1116-28. PMC: 3864893. DOI: 10.1016/j.molonc.2013.08.007. View